Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyeChild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia
2024-516112-21-00Phase 3Authorised
- Sponsor
- University of Birmingham
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Extramedullary leukemia (EML) (9 arms), sponsored by University of Birmingham. Planned start Dec 2024; status: authorised.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Extramedullary leukemia (EML)
Beyond the preview
Go deeper on 2024-516112-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516112-21-00.